Studies from the National Institute on Aging examining body composition changes during GLP-1 therapy show that individuals over 50 who lost significant lean mass experienced measurable declines in grip strength, gait speed, and activities of daily living scores
Additionally, in UC samples there was an increase in Coprococcus and Faecalibacterium compared to healthy controls [133, 134]
Competitive Positioning: Differentiate MariTide against market leaders like semaglutide and tirzepatide
While both medications are developed by Eli Lilly, Retatrutides triple action gives it an edge over tirzepatide, a dual agonist
Diese Entwicklungen werfen wichtige Fragen auf: Werden endoskopische Verfahren noch bentigt, wenn Medikamente so effektiv sind
Focus on smaller, more frequent meals with lean proteins, complex carbohydrates, and vegetables